

Metmot A/#5
2 39/02

Treliminary Amendment
Page 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

ANDERSON et al. * Group Art Unit: Unassigned

*

Application Serial No. (Unassigned)

Examiner: Unassigned

Filed: July 25, 2001

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents Washington, DC 20231

Sir:

Prior to examination, kindly amend the claims as follows.

IN THE CLAIMS

Please cancel all of original claims 1-20 and enter the following new claims 21 to 69:

- 21. A chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:6 and a variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.
- 22. An anti-CD20 variable light chain encoded by the nucleic acid sequence in SEQ ID NO:6.
- 23. An anti-CD20 variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.
- 24. A chimeric anti-CD20 antibody having a variable light chain encoded by the nucleic acid sequence in SEQ ID NO:6.
- 25. A chimeric anti-CD20 antibody having a variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.
- 26. The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.